Roche Holding AG

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (eBC) who have residual invasive disease following neoadjuvant (before surgery) treatment. A statistically significant and clinically meaningful improvement in overall survival (OS), a secondary endpoint, was observed with adjuvant (post-surgery) Kadcyla® (trastuzumab emtansine) compared to Herceptin® (trastuzumab): at the 7-year landmark OS rates were 89.07% and 84.37% with Kadcyla and Herceptin, respectively (hazard ratio [HR]=0.66, 95% CI: (0.51, 0.87), p-value =0.0027).2 Data also show that the previously reported invasive disease-free survival (primary endpoint) benefit is maintained.2 Kadcyla reduced the risk of disease recurrence or death from any cause by 46% compared to Herceptin (HR=0.54, 95% CI: (0.44, 0.66), p-value

Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment

Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance®) and fulvestrant as a first-line treatment for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.1

Roche's inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance®) and fulvestrant as a first-line treatment for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. The inavolisib combination reduced the risk of disease worsening.

Genentech's Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive long-term follow-up data from the pivotal, Phase III KATHERINE study in people with HER2-positive early-stage breast cancer (eBC) who have residual invasive disease following neoadjuvant (before surgery) treatment. A statistically significant and clinically meaningful improvement in overall survival (OS), a secondary endpoint, was observed with adjuvant (po.

Genentech's Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment

Roche's (RHHBY) phase III study evaluating inavolisib in combination with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation achieves its primary goal.

Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III

Basel, 5 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance®) and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. The study met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant and clinically meaningful improvement compared to palbociclib and fulvestrant alone. Overall survival data were immature at this time, but a clear positive trend has been observed. Follow-up will continue to the next analysis.

Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance®) and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. The study met its primary.

Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

Roche Holding AG is the latest drug maker trying to take advantage of the booming demand for weight-loss drugs.

Roche Buys Carmot Therapeutics to Compete in Booming Market for Weight-Loss Drugs

Roche said Carmot Therapeutics' research and development portfolio “has great potential to treat obesity, diabetes and potentially other diseases” both on its own and in combination with Roche's assets.

Roche Will Buy Obesity And Diabetes Drugmaker Carmot Therapeutics In $2.7 Billion Deal

Roche (RHHBY) aims to enter the promising and much-in-demand obesity drug market with the acquisition of Carmot Therapeutics, Inc. for $2.7 billion.

Roche (RHHBY) to Acquire Obesity Drug Maker Carmot for $2.7B

Roche is expanding its obesity drug pipeline with the acquisition of Carmot Therapeutics for up to US$3.1 billion. Per the agreement, Roche will pay US$2.7 billion upfront to acquire private biotechnology firm Carmot with additional milestone payments of up to US$400 million available.

Roche to acquire obesity drugmaker Carmot Therapeutics for up to US$3.1B

Roche said it will spend up to $3.1 billion to acquire Carmot Therapeutics, a biotech firm developing obesity drugs.

Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker

Roche Holding AG Genussscheine (SWX: ROG) says it will acquire Carmot Therapeutics for $2.7 billion in cash. Its shares are up 3.0% at writing.

Roche is buying Carmot to enter anti-obesity market

Roche is to acquire anti obesity drug developer Carmot Therapeutics, becoming the latest pharma company to enter the global weight-loss drugs market.

Roche enters obesity market with Carmot takeover but drugs may not be available until 2030

Eli Lilly

Novo Nordisk

Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion. The Swiss company is hoping to join Eli Lilly and Novo Nordisk at the forefront of the weight-loss drug market.

Roche Strikes $3.1 Billion Deal for Obesity Drugmaker. It Hopes to Compete with Eli Lilly, Novo Nordisk.

Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion, as the world's top drugmakers rush to capitalize on the booming market for weight-loss drugs that has seen Novo Nordisk become Europe's most valuable company.

Roche strikes $3.1 billion deal to buy obesity-drug maker Carmot Therapeutics billion in race to rival Novo Nordisk's Ozempic

Pharmaceutical giant Roche said on Monday it has entered into a definitive agreement to acquire Carmot Therapeutics , a US company based in Berkeley.

Roche to acquire Carmot Therapeutics for $2.7 bln

Basel, 4 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc. (“Carmot”), a privately owned US company based in Berkeley, California. Carmot's R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes

– Roche to acquire Carmot for an upfront payment of $2.7 billion and the potential for $400 million in milestone payments –

Carmot Therapeutics Enters into Definitive Merger Agreement with Roche

SEATTLE, Nov. 30, 2023 (GLOBE NEWSWIRE) -- ShapeTX announced today the expansion of its partnership with Roche, with Roche adding a new target to their ongoing collaboration, which was initially established in August 2021 . This expansion marks the beginning of a new program where ShapeTX will use its proprietary AI-powered RNA editing platform to develop a potential one-time therapy for patients with high unmet needs for an undisclosed disease affecting millions of people worldwide.

ShapeTX Expands Strategic Collaboration with Roche with Addition of a New Target

After a 14% fall this year, Roche stock (OTCMKTS: RHHBY) looks like it can see higher levels.

Is Roche Stock Undervalued At $33?

Basel, 27 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of Elecsys® HBeAg quant, an immunoassay that is able to determine both the presence and quantity (qualitative and quantitative) of the hepatitis B e antigen (HBeAg) in human serum and plasma. This launch means that, when combined with other laboratory results and clinical information, patients will now get confirmation on whether they have hepatitis B (HBV), and if so, to what extent, as well as treatment monitoring through one single assay. It is for use on the cobas® e analysers in countries accepting the CE Mark. HBV is the most common type of viral hepatitis affecting people of all ages, posing a significant burden on people and healthcare systems globally.1

Roche expands hepatitis diagnostics portfolio to help clinicians diagnose and monitor patients with acute or chronic hepatitis B infection

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced a multi-year strategic research collaboration with NVIDIA that couples Genentech's artificial intelligence (AI) capabilities, extensive biological and molecular datasets, and research expertise with NVIDIA's world-leading accelerated computing capabilities and AI to speed up drug discovery and development. The collaboration is designed to significantly enhance Genen.

Genentech and NVIDIA Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Development

The LightCycler PRO System is designed to be the most advanced qPCR technology for both clinical diagnostics and research. The new system will advance personalised healthcare and support outbreak readiness by delivering agility and flexibility for translational research and diagnostics.

Roche launches next-generation qPCR system to advance clinical needs in molecular diagnostics and address public health challenges

Swiss drugs and diagnostics maker Roche is investing $240 million in Colombia over five years as part of its plan to consolidate its presence in the country, a high-ranking executive said on Thursday.

News for Roche Holding AG Stock (RHHBY)